Onxeo Changes Its Name and Becomes Valerio Therapeutics Following Approval by the Annual General Meeting of June 6, 2023

All the resolutions approved by the Board of Directors were adopted

PARIS--(BUSINESS WIRE)--Regulatory News:

Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, announced that the Annual General Meeting held today at 2pm CEST was able to validly deliberate with a quorum of 44.12% , with 30 shareholders representing 49,072,091 voting rights.

The Annual General Meeting followed the voting recommendations of the Board of Directors for all resolutions, approving the 2022 financial statements and the renewal of the terms of Robert Coleman, independent director, and Nicolas Trebouta, permanent representative of the historical shareholder Financière de la Montagne.

The Annual General Meeting also approved the change of company name to Valerio Therapeutics. This name change is accompanied by a new identity, to be presented in the coming weeks, designed to better represent Valerio Therapeutics' ability to rapidly advance breakthrough therapeutic candidates through Phase 2 development, and to collaborate with partners for further development and commercialization. The ISIN code will remain unchanged.

Shefali Agarwal, President and Chief Executive Officer, stated: “I would like to thank all our shareholders for their participation and support at this Annual General Meeting, which marks a real milestone for our Company. We are proud to present our new company name today, conveying values of strength, health, resilience, vitality and robustness. In addition, the Valerio name has a timeless, traditional essence that matches the company's positioning as a clinical-stage biotechnology company focused on developing innovative therapies using cutting-edge technology platforms to revolutionize cancer treatment and improve patient outcomes. Valerio also represents a sense of legacy and endurance, thus becoming part of Onxeo's history and writing a new page over the long term.”

The consolidated result of the vote by resolution and the minutes of the General Meeting will be available within the legal deadlines on the Company's website, in the General Meetings section.

Next financial release

Half-year 2023 results: Thursday, September 28, 2023, after market close

About Onxeo

Onxeo (Euronext Growth Paris: ALONX) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

PlatON is Onxeo’s proprietary chemistry platform of DNA decoy therapeutics, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA, the first compound from platON, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its DNA decoy therapeutic mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently being studied in Europe and the US in combination with other treatment modalities in difficult-to-treat solid tumors.

OX425, the second compound from platON, is a novel pan-DDR Decoy with high antitumor activity. It also mediates multiple immunostimulatory effects by activating the STING pathway. OX425 is currently undergoing IND-enabling preclinical development.

For further information, please visit www.onxeo.com.

Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org).

Onxeo
Investor Relations
investors@onxeo.com
+33 1 45 58 76 00

Media Relations
Arthur Rouillé
NewCap
onxeo@newcap.eu
+33 1 44 71 00 15

Investor Relations / Strategic Communication
Dušan Orešanský / Nicolas Fossiez
NewCap
onxeo@newcap.eu
+33 1 44 71 94 92